Advertisement
Device Sectors
Subscribe to Device Sectors
View Sample

FREE Email Newsletter

Oridion Medical and Philips Healthcare Microstream CO2 Filterline (FilterLine H Set Infant/Neonate, VitaLine H Set Infant/Neonate: Recall - Plastic Strands on the Adapter May ...

June 7, 2011 6:30 am | by U.S. Food & Drug Administration | News | Comments

Inhalation of the plastic strands may cause respiratory compromise, which could result in serious illness or death.

Vendor Neutral Archiving: What the NHS Should Expect

June 7, 2011 3:31 am | by RealWire | News | Comments

Free whitepaper from BridgeHead Software explains how vendor neutral archives (VNAs) can help the NHS reduce IT costs, increase efficiency and improve data protectionAshtead, UK - Tuesday 7th June - BridgeHead Software, a leader in healthcare data and storage management, today released a...

VEGF Trap-Eye Submitted for EU Marketing Authorization for Treatment of Wet Age-Related Macular Degeneration

June 6, 2011 11:33 pm | by Bio-Medicine.Org | News | Comments

TARRYTOWN, N.Y. and BERLIN, June 7, 2011 /- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) and Bayer HealthCare today announced that Bayer HealthCare has submitted an application for marketing authorization in Europe for VEGF Trap-Eye for the treatment of the neovascular form of...

Advertisement

Apricoxib Prolongs Time-to-Progression and Overall Survival in Biomarker-Selected NSCLC Patients

June 6, 2011 5:33 pm | by Bio-Medicine.Org | News | Comments

CHICAGO and SAN DIEGO, June 6, 2011 /- Tragara Pharmaceuticals, Inc. announced today that apricoxib (Capoxigem®, TG01) in combination with erlotinib demonstrated significant and consistent clinical benefit over erlotinib alone in a clinically relevant subset of biomarker-selected...

The Premier Basketball League Brings on Key Health Industry Sponsorship for 2012

June 6, 2011 2:35 pm | by Bio-Medicine.Org | News | Comments

CHICAGO, June 6, 2011 /- The Premier Basketball League announced today that Scientific Imaginetics® , the global leader in non-invasive pain relief technology, has come on board as a corporate sponsor for the 2012 PBL season. Scientific Imaginetics' TMR® technology is a...

Crux Successfully Completes Funding for Advanced Filter for PE Prevention

June 6, 2011 2:34 pm | by Bio-Medicine.Org | News | Comments

MENLO PARK, Calif., June 6, 2011 /- Crux Biomedical Inc., a developer of an advanced implantable vena cava filter (VCF), announced the successful completion a $12.0MM investment round.  The round was led by Three Arch Partners, which was joined by current investors, Alloy Ventures...

Class I Medical Device Recall: Oridion Medical and Philips Healthcare Microstream CO2 Filterline (FilterLine H Set Infant/Neonate, VitaLine H Set Infant/Neonate)

June 6, 2011 12:30 pm | by U.S. Food & Drug Administration | News | Comments

Reason for Recall: Fine plastic strands on the inner surface of the infant/neonatal airway adapter may become dislodged and inhaled by the patient. Inhalation of the plastic strands on the defective devices may cause respiratory compromise, which could...

Grifols Announces the Appointment of Thomas Glanzmann as Chairman of its New Board of Directors for U.S. Operations

June 6, 2011 11:36 am | by Bio-Medicine.Org | News | Comments

RESEARCH TRIANGLE PARK, N.C., June 6, 2011 /- (NASDAQ: GRFS).  Grifols, a global healthcare company and biopharmaceutical manufacturer based in Barcelona, Spain, today announced the establishment of a new Board of Directors for its U.S. operations, including the appointment of Thomas...

Advertisement

AmeriCares Honors AstraZeneca with Power of Partnership Award

June 6, 2011 11:35 am | by Bio-Medicine.Org | News | Comments

STAMFORD, Conn., June 6, 2011 /PRNewswire-USNewswire/ -- AmeriCares has awarded its annual Power of Partnership Award to AstraZeneca for its outstanding commitment to increasing access to health care for people in need both here at home and throughout the developing world.  In the...

Aeolus Pharmaceuticals, Inc. Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com

June 6, 2011 11:35 am | by Bio-Medicine.Org | News | Comments

NEW YORK,  June 6, 2011 /- Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) today announced that their June 2nd RetailInvestorConferences.com presentation is available for on-demand viewing. LINK: www.retailinvestorconferences.com > Click the red "register/ watch event now" button....

Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atheroscleroti...

June 6, 2011 11:35 am | by Bio-Medicine.Org | News | Comments

LA JOLLA, Calif., June 6, 2011 – Regulus Therapeutics Inc ., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced publication in the Journal of Clinical Investigation of new pre-clinical data in mice on the...

SuperGen, Inc. Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com

June 6, 2011 11:35 am | by Bio-Medicine.Org | News | Comments

NEW YORK June 6, 2011 /- SuperGen, Inc. (NASDAQ: SUPG ), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced their June 2nd RetailInvestorConferences.com presentation is available for on-demand viewing. LINK:...

Voluntary Worldwide Field Correction Issued for the S98/98XT, CS100/CS100i and CS300 Intra-Aortic Balloon Pumps

June 6, 2011 11:35 am | by Bio-Medicine.Org | News | Comments

MAHWAH, N.J., June 6, 2011 /- In March 2011, Datascope Corp/Maquet initiated a voluntary worldwide field correction of certain Intra-Aortic Balloon Pumps (IABPs) sold under the Datascope Corp. System 98/98XT (Part numbers: 0998-00-0446-xx, 0998-UC-0446-xx, 0998-00-0479-xx,...

Advertisement

FDA News & Notes - Week of June 6, 2011

June 6, 2011 11:35 am | by Bio-Medicine.Org | News | Comments

SILVER SPRING, Md., June 6, 2011 /PRNewswire-USNewswire/ -- Science, public health, and regulatory highlights for this week from the U.S. Food and Drug Administration. Information in this document is designed for credentialed journalists. Release dates and times for items are current as...

RF Technologies® Releases Code Alert® Quick Response® Wireless Call Solutions

June 6, 2011 11:35 am | by Bio-Medicine.Org | News | Comments

BROOKFIELD, Wis., June 6, 2011 /- RF Technologies®, a leading provider of radio frequency identification monitoring systems and healthcare security solutions, announces the release of Code Alert ® Quick Response ® Wireless Call Solutions. Available in three options so...

COPAN Announces Strategic Global Distribution Partnership with Siemens

June 6, 2011 11:35 am | by Bio-Medicine.Org | News | Comments

MURRIETA, Calif., June 6, 2011 /- COPAN announced a strategic partnership with Siemens for the global distribution of COPAN WASP®: Walk-Away Specimen Processor in New Orleans, Louisiana, during the ASM's 111th General Meeting. The strategic distribution partnership announcement came...

American Scientific Resources Will be a Presenter at the Undiscovered Equities Spring Conference in Boca Raton

June 6, 2011 11:34 am | by Bio-Medicine.Org | News | Comments

WESTON, Fla., June 6, 2011 /- American Scientific Resources, Incorporated (OTCQB: ASFX) (the "Company") will be presenting at the Undiscovered Equities Spring Conference held in Boca Raton, Florida on Wednesday, June 8, 2011 at Ruth's Chris Steak House, 999 East Camino Real, Boca Raton,...

PMA Final Decisions for April 2011

June 6, 2011 10:31 am | by U.S. Food & Drug Administration | News | Comments

These are Premarket Approvals (PMA), Product Development Protocols (PDP), Supplement and Notice Decisions for April 2011.

Cancer vaccines come of age with positive clinical data

June 6, 2011 7:35 am | by Mass High Tech: The Journal of New England Technology | News | Comments

A new form of treatment that goes beyond oncology drugs and surgery is now coming of age: cancer vaccines. At the American Society of Clinical Oncology meeting in Chicago over the weekend - a major forum for cancer researchers - several companies and research groups reported progress on...

Uroplasty's Dave Kaysen to Ring NASDAQ Closing Bell

June 6, 2011 3:36 am | by Bio-Medicine.Org | News | Comments

MINNEAPOLIS, June 6, 2011 /- Uroplasty, Inc. (NASDAQ: UPI ), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, announced today that its President and CEO David Kaysen will ring the NASDAQ Stock Market Closing...

FREEDOM-M Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Meets Primary Endpoint

June 6, 2011 3:33 am | by Bio-Medicine.Org | News | Comments

SILVER SPRING, Md., June 6, 2011 /- United Therapeutics Corporation (NASDAQ: UTHR ) announced today the completion of its FREEDOM-M Phase 3 trial of treprostinil diethanolamine (oral treprostinil), an investigational sustained release oral formulation of treprostinil, a stable synthetic...

University Hospitals Seidman Cancer Center Opens: First Cancer Hospital in Northeast Ohio Offers Nation's Most Advanced Technology and Treatments

June 6, 2011 3:33 am | by Bio-Medicine.Org | News | Comments

CLEVELAND, June 6, 2011 /- University Hospitals (UH) Seidman Cancer Center, Northeast Ohio's first and only freestanding cancer hospital, opens to patients on June 6. The ten-story, 150-bed cancer hospital will house the latest cancer-fighting treatments and technology – all in a...

Life Technologies Develops Fast and Accurate Test to Detect Europe's Deadly E. coli

June 6, 2011 3:32 am | by Bio-Medicine.Org | News | Comments

CARLSBAD, Calif., June 6, 2011 /- Life Technologies Corporation (NASDAQ: LIFE ) today announced that it has developed a custom test (assay) to accurately detect the E. coli bacterium that has killed at least 22 people and affected more than 2,100 worldwide, including four new cases...

Bayer's Investigational Compound Radium-223 Chloride Met its Primary Endpoint of Significantly Improving Overall Survival in a Phase III Trial in Patients with Castration-Resi...

June 5, 2011 11:35 pm | by Bio-Medicine.Org | News | Comments

WAYNE, N.J., June 6, 2011 /- Bayer HealthCare Pharmaceuticals Inc. today announced that the Phase III ALSYMPCA ( AL pharadin in SYM ptomatic P rostate CA ncer) trial evaluating Bayer's investigational compound, radium-223 chloride, which is exclusively licensed from Algeta ASA, in...

ZALTRAPâ„¢ (aflibercept) Significantly Improved Survival in Previously Treated Metastatic Colorectal Cancer Patients

June 5, 2011 11:35 pm | by Bio-Medicine.Org | News | Comments

PARIS and TARRYTOWN, N.Y., June 6, 2011 /- Sanofi (EURONEXT: SAN and NYSE: SNY ) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that data showing that the investigational agent ZALTRAP™ (aflibercept), also known as VEGF Trap, significantly improved survival in...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading